Dexrazoxane Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 500 mg/50 mL, 250 mg/25 mL
Reference Brands: Zinecard (USA), Totect (USA), Cardioxane (EU)
Category:
Oncology Cancer Care
Dexrazoxane Hydrochloride is available in Injection
and strengths such as 500 mg/50 mL, 250 mg/25 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dexrazoxane Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dexrazoxane Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dexrazoxane hydrochloride is a cardioprotective agent used in oncology to minimize the risk of heart damage caused by anthracycline chemotherapy, such as doxorubicin and daunorubicin. Discovered in 1972, it is administered intravenously under acidic conditions, with hydrochloric acid used to adjust the solution’s pH for stability and efficacy. Dexrazoxane works by chelating iron and preventing the formation of free radicals, which are responsible for chemotherapy-induced cardiotoxicity.
Initially, regulatory restrictions limited its use in pediatric patients due to concerns over secondary malignancies and acute myeloid leukemia when used alongside anthracyclines. However, updated guidance from the European Medicines Agency and European Commission has allowed dexrazoxane to be used for primary prevention of anthracycline-induced cardiotoxicity in children and adolescents under carefully monitored conditions.
Dexrazoxane hydrochloride is also used as an antidote for anthracycline extravasation, reducing tissue injury at the site of accidental drug leakage. It is available under brand names such as Zinecard and Cardioxane, and is supplied as an injectable solution for intravenous administration, providing effective cardioprotection while allowing patients to continue life-saving chemotherapy regimens.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing